OKYO Pharma Limited Director/PDMR Shareholding (1394U)
March 24 2023 - 3:00AM
UK Regulatory
TIDMOKYO
RNS Number : 1394U
OKYO Pharma Limited
24 March 2023
PDMR Dealing
London and New York, NY, 24 March, 2023 - OKYO Pharma Limited
(Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an
ophthalmology-focused bio-pharmaceutical company which is
developing OK-101 to treat dry eye disease ("DED") to address the
significant unmet need in this multi-billion-dollar market, today
announces that it has been notified that Panetta Partners Limited,
an entity in which Gabriele Cerrone, the Executive Chairman has a
beneficial interest, purchased 10,000 of the Company's ADSs on
NASDAQ at a price of US$1.40 per ADS (which would be equivalent to
the purchase of 650,000 ordinary shares of no par value ("Ordinary
Shares") at a price of GBP0.0175 each).
1. Details of PDMR / person closely associated
a) Name Gabriele Cerrone
------------------ -----------------------------------------------------
2. Reason for the notification
-------------------------------------------------------------------------
a) Position Chairman
/ status
------------------ -----------------------------------------------------
b) Initial Initial notification
notification
/amendment
------------------ -----------------------------------------------------
3. Details of the issuer
-------------------------------------------------------------------------
a) Name OKYO Pharma Limited
------------------ -----------------------------------------------------
b) LEI 213800VVN5CB56Y15A05
------------------ -----------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description ADSs representing 65 Ordinary Shares of no par value
of the
financial
instrument
------------------ -----------------------------------------------------
b) Identification ISIN for OKYO Pharma Limited GG00BD3FV870
code of
the Financial
Instrument
------------------ -----------------------------------------------------
c) Nature Market Purchase
of the
transaction
------------------ -----------------------------------------------------
Price(s)
d) and volume(s) $1.40 - 10,000
------------------ -----------------------------------------------------
f) Date of 23 March 2023
the transaction
------------------ -----------------------------------------------------
g) Place of NASDAQ
the transaction
------------------ -----------------------------------------------------
Enquiries:
OKYO Pharma Gary S. Jacob, Chief Executive
Limited Officer +44 (0)20 7495 2379
Investor Relations Paul Spencer +44 (0)20 7495 2379
Robert Emmet, Optiva Securities
Broker Limited +44 (0)20 3981 4173
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences
company admitted to listing on NASDAQ and on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain. For further information, please visit www.okyopharma.com
.
About OK-101
OK-101 is a lipid conjugated chemerin peptide antagonist of the
ChemR23 G-protein coupled receptor which is typically found on
immune cells of the eye responsible for the inflammatory response.
OK-101 was developed using a membrane-anchored-peptide (MAP)
technology to produce a novel long-acting drug candidate for
treating dry eye disease. OK-101 has been shown to produce
anti-inflammatory and pain-reducing activities in mouse models of
dry eye disease and corneal neuropathic pain; and is designed to
combat washout through the inclusion of the lipid 'anchor'
contained in the candidate drug molecule to enhance the residence
time of OK-101 within the ocular environment.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHZZLBLXXLLBBV
(END) Dow Jones Newswires
March 24, 2023 03:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Jul 2024 to Aug 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Aug 2023 to Aug 2024